The firms will initially develop a tool to identify NSCLC patients with EGFR mutations who can benefit from targeted therapy.
Nov 5 (Reuters) - AstraZeneca (AZN.L), opens new tab shares on Tuesday recorded their worst day since March 2020 after a report that dozens of the drugmaker's senior executives in China could be ...
LONDON, United Kingdom - AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an early-stage trial, with side effects consistent with ...
Pharmaceutical giant AstraZeneca, whose China president is under investigation, was previously investigated for medical insurance fraud cases involving cancer medication sales, according to new ...
SAN AN­TO­NIO — Well be­hind No­vo Nordisk and Eli Lil­ly in the obe­si­ty race, As­traZeneca came to this year’s Obe­si­ty­Week with three as­sets in hand … ...
From big pharmaceutical companies such as AstraZeneca to small biotechnology firms like Amicus Therapeutics of New Jersey, which is looking for a non-Chinese company to supply raw materials for ...
Two days after AstraZeneca announced that Wang Lei, head of its China operations, is under investigation, questions are growing over the company’s role within China’s health care sector. The ...
This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...
BEIJING - The head of multinational pharmaceutical giant AstraZeneca’s China arm is under investigation in the country, the firm said. Mr Leon Wang, president of AstraZeneca China, is ...
Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development, and diagnostics, has announced MSIntuit CRC v21, a next-generation AI solution.
AstraZeneca’s China president is under investigation in mainland China, the drug company said on Wednesday. Leon Wang was described as cooperating “with an ongoing investigation”, the ...